Merus Presents Interim Data on MCLA-129 at ESMO Asia Congress 2023
December 02, 2023 20:40 ET
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing...
Merus Announces Publication of Abstracts on MCLA-129 for Presentation at ESMO Asia Congress 2023
November 26, 2023 11:05 ET
|
Merus N.V.
- Oral presentation on MCLA-129 in combination with osimertinib as first line therapy, and in previously treated, NSCLC on Sunday, December 3 at 9:40 a.m. SGT - Poster presentation on MCLA-129 in...
Merus Announces Financial Results for the Third Quarter 2023 and Provides Business Update
November 02, 2023 16:12 ET
|
Merus N.V.
– Petosemtamab in combination with Keytruda 1L initial interim clinical data planned for 1H24; 2L+ HNSCC monotherapy clinical update planned 2024 – Zeno interim clinical data continue to show robust...
Merus to Participate in Upcoming Investor Conferences
November 01, 2023 08:00 ET
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific...
Merus’ Zeno Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ Cancer
October 23, 2023 07:30 ET
|
Merus N.V.
- 37% ORR and 14.9 months median DOR in 78 evaluable NRG1+ NSCLC patients - 42% ORR and 9.1 months median DOR in 33 evaluable NRG1+ PDAC patients - Sufficient clinical data expected in 1H24 to...
Merus Announces Business Update Conference Call
October 15, 2023 19:58 ET
|
Merus N.V.
Zeno interim clinical data continues to show robust efficacy in NRG1+ NSCLC and PDAC: Sufficient clinical data expected in 1H24 to support potential BLA submissions Petosemtamab 2L+ HNSCC phase 3...
Merus Announces Abstracts Accepted for Presentation at the ESMO Asia Congress 2023
October 06, 2023 09:32 ET
|
Merus N.V.
Mini Oral: MCLA-129 in combination with osimertinib in treatment naïve, and after progression on osimertinib, non-small cell lung cancer Poster: MCLA-129 in previously treated head & neck...
Merus to Participate in Upcoming Investor Conferences
August 31, 2023 08:00 ET
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific...
Merus N.V. Announces Proposed Public Offering of Common Shares
August 09, 2023 16:01 ET
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing...
Merus Announces Financial Results for the Second Quarter 2023 and Provides Business Update
August 07, 2023 16:26 ET
|
Merus N.V.
– Petosemtamab granted Fast Track Designation for the treatment of patients with recurrent or metastatic head & neck squamous cell carcinoma – Phase 3 trial of petosemtamab monotherapy in...